Effects of Policosanol on Borderline to Mildly Elevated Serum Total Cholesterol Levels: A Prospective, Double-Blind, Placebo-Controlled, Parallel-Group, Comparative Study

Current Therapeutic Research - Clinical and Experimental

Volumn 64, Issue 8, 2003, Pages 522-537

  Castaño, Gladys ^a   Más, Rosa ^a   Fernández, Julio ^a   López, Ernesto ^a   Illnait, José ^a   Fernández, Lilia ^a   Mesa, Meylin ^a  

^a NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

Borderline dyslipidemia; Cholesterol lowering drugs; Hypercholesterolemia; Policosanol

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; POLICOSANOL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; DRY SKIN; FEMALE; HEADACHE; HEARTBURN; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LABORATORY TEST; LIFESTYLE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; SUGARCANE; TREATMENT OUTCOME;

EID: 0344945606     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.curtheres.2003.09.002     Document Type: Article

References (48)

1. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation. 1991;83:356-362.
2. The Lipid Research Clinics Coronary Primary Prevention Trial results. 1. Reduction in incidence of coronary heart disease. JAMA. 1984;251:351-364.
3. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in the incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365-374.
4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
5. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med. 1996;335:1001-1009.
6. Prevention of cardiovascular events and deaths with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339:1349-1357.
7. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-1622.
8. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
9. Expert Panel of Detection, Evaluation and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
10. Wood D. European and American recommendations for coronary heart disease prevention. Eur Heart J. 1998;19(Suppl A):A12-A19.
11. Gotto AM, Assman G, Carmena R, et al. The ILIB Lipid Handbook for Clinical Practice. Blood Lipids and Coronary Heart Disease. 2d ed. New York: International Lipid Information Bureau (ILIB); 2000.
12. Illingworth DR, Tobert JA. A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin Ther. 1994;16:366-385.
13. Grundy SM. Statin trials and goals of cholesterol-lowering therapy. Circulation. 1998;97:1436-1439.
14. Hsu I, Spinler SA, Johnson NE. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann Pharmacother. 1995;29:743-759.
15. Baker SK, Tarnopolsky MA. Statin myopathies: Pathophysiologic and clinical perspectives. Clin Invest Med. 2001;24:258-272.
16. Más R. Policosanol. Drugs of the Future. 2000;25:569-586.
17. Pons P, Rodriguez M, Robaina C, et al. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolaemia and tolerability to treatment. Int J Clin Pharmacol Res. 1994;14:27-33.
18. Canetti M, Moreira M, Más R, et al. A two-year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinaemia. Int J Clin Pharmacol Res. 1995;15:159-165.
19. Benitez M, Romero C, Más R, et al. A comparative study of policosanol versus pravastatin in patients with type II hypercholesterolemia. Curr Ther Res Clin Exp. 1997;58:859-867.
20. Más R, Castaño G, Illnait J, et al. Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors. Clin Pharmacol Ther. 1999;65:439-447.
21. Castaño G, Más R, Fernández L, et al. Effect of policosanol on postmenopausal women with type II hypercholesterolemia. Gynecol Endocrinol. 2000;14:187-195.
22. Castaño G, Más R, Arruzazabala ML, et al. Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients. Int J Clin Pharm Res. 1999;19:105-116.
23. Castaño G, Más R, Fernández JC, et al. Effects of policosanol in older patients with type II hypercholesterolemia and high coronary risk. J Gerontol A Biol Sci Med Sci. 2001;56:M186-M192.
24. Fernández JC, Más R, Castaño G, et al. Comparison of the efficacy, safety and tolerability of policosanol versus fluvastatin in elderly hypercholesterolemic women. Clin Drug Invest. 2001;21:103-113.
25. Más R, Castaño G, Fernández L, et al. Effects of policosanol in older hypercholesterolemic patients with coronary disease. Clin Drug Invest. 2001;21:485-497.
26. Torres O, Agramonte AJ, Illnait J, et al. Treatment of hypercholesterolemia in NIDDM with policosanol. Diabetes Care. 1995;18:393-397.
27. Crespo N, Illnait J, Más R, et al. Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and noninsulin dependent diabetes mellitus. Int J Clin Pharmacol Res. 1999;19:117-127.
28. Menéndez R, Fernández SI, Del Rio A, et al. Policosanol inhibits cholesterol biosynthesis and enhances low density lipoprotein processing in cultured human fibroblasts. Biol Res. 1994;27:199-203.
29. Menéndez R, Arruzazabala ML, Más R, et al. Cholesterol-lowering effect of policosanol on rabbits with hypercholesterolaemia induced by a wheat starch-casein diet. Br J Nutr. 1996;77:923-932.
30. Menéndez R, Amor AM, Rodeiro I, et al. Policosanol modulates HMG-CoA reductase activity in cultured fibroblasts. Arch Med Res. 2001;32:8-12.
31. Fernández L, Más R, Illnait J, Fernandez JC. Policosanol: Results of a postmarketing surveillance study of 27,879 patients. Curr Ther Res Clin Exp. 1998;59:717-722.
32. Más R, Rivas P, Izquierdo JE, et al. Pharmacoepidemiologic study of policosanol. Curr Ther Res Clin Exp. 1999;60:458-467.
33. Schectman G, Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: Factors limiting achievement of lipid goals. Am J Med. 1996;100:197-204.
34. Seigler L, Wu WT. Separation of serum high-density lipoprotein for cholesterol determination: Ultracentrifugation vs precipitation with sodium phosphotungstate and magnesium chloride. Clin Chem. 1981;27:838-841.
35. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
36. Smith DG, Leslie SJ, Szucs TD, et al. Cost of treating to a modified European Atheroesclerosis Society LDL-C Target. Comparison of atorvastatin with fluvastatin, pravastatin and simvastatin. Clin Drug Invest. 1999;17:185-193.
37. Arruzazabala ML, Carbajal D, Más R, et al. Effects of Policosanol on platelet aggregation in rats. Thromb Res. 1993;69:321-327.
38. Arruzazabala ML, Molina V, Carbajal D, et al. Effect of policosanol on cerebral ischemia in Mongolian gerbils: Role of prostacyclin and thromboxane A2. Prostaglandins Leukot Essent Fatty Acids. 1993;49:695-697.
39. Valdes S, Arruzazabala ML, Fernandez L, et al. Effect of policosanol on platelet aggregation in healthy volunteers. Int J Clin Pharmacol Res. 1996;16:67-72.
40. Arruzazabala ML, Valdes S, Más R, et al. Effect of policosanol successive dose increases on platelet aggregation in healthy volunteers. Pharmacol Res. 1996;34:181-185.
41. Arruzazabala ML, Valdes S, Más R, et al. Comparative study of policosanol, aspirin and the combination therapy policosanol-aspirin on platelet aggregation in healthy volunteers. Pharmacol Res. 1997;36:293-297.
42. Carbajal D, Arruzazabala ML, Valdes S, Más R. Interaction policosanol-warfarin on bleeding time and thrombosis in rats. Pharmacol Res. 1998;38:89-91.
43. Arruzazabala ML, Más R, Molina V, et al. Effect of policosanol on platelet aggregation in type 11 hypercholesterolemic patients. Int J Tissue React. 1998;20:119-124.
44. Castaño G, Fernández L, Más R, et al. Comparison of the effects of policosanol and atorvastatin on lipid profile and platelet aggregation on patients with dyslipidemia and type 2 diabetes mellitus. Clin Drug Invest. 2003. In press.
45. Menéndez R, Más R, Amor AM, et al. Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro. Br J Clin Pharmacol. 2000;50:255-262.
46. Menéndez R, Más R, Amor AM, et al. Effects of policosanol on the susceptibility of low-density lipoprotein isolated from hypercholesterolemic patients at high coronary risk to in vitro copper-mediated lipid peroxidation: A randomized, double-blind pilot study. Curr Ther Res Clin Exp. 2000;61:609-620.
47. Más R, Castaño G, Fernández J, et al. Effects of policosanol (5-10 mg/day) in older hypercholesterolemic patients. J Am Coll Cardiol. 2002;39(Suppl B):Number 9. Abstract.
48. Molina Cuevas V, Arruzazabala ML, Carbajal Quintana D, et al. Effect of policosanol on arterial blood pressure in rats. Study of the pharmacological interaction with nifedipine and propranolol. Arch Med Res. 1998;29:21-24.